JPWO2022018875A1 - - Google Patents

Info

Publication number
JPWO2022018875A1
JPWO2022018875A1 JP2022538564A JP2022538564A JPWO2022018875A1 JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1 JP 2022538564 A JP2022538564 A JP 2022538564A JP 2022538564 A JP2022538564 A JP 2022538564A JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538564A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP2021121960A priority Critical patent/JP7168734B2/ja
Publication of JPWO2022018875A1 publication Critical patent/JPWO2022018875A1/ja
Priority to JP2022172687A priority patent/JP2023011759A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
JP2022538564A 2020-07-22 2020-07-22 Pending JPWO2022018875A1 (xx)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021121960A JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/028575 WO2022018875A1 (ja) 2020-07-22 2020-07-22 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
JPWO2022018875A1 true JPWO2022018875A1 (xx) 2022-01-27

Family

ID=79729374

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022538564A Pending JPWO2022018875A1 (xx) 2020-07-22 2020-07-22
JP2021121960A Active JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A Pending JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021121960A Active JP7168734B2 (ja) 2020-07-22 2021-07-26 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP2022172687A Pending JP2023011759A (ja) 2020-07-22 2022-10-27 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Country Status (3)

Country Link
JP (3) JPWO2022018875A1 (xx)
KR (2) KR102550455B1 (xx)
WO (1) WO2022018875A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023204259A1 (ja) * 2022-04-20 2023-10-26 中外製薬株式会社 がんの治療又は予防用医薬
WO2024010925A2 (en) * 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200520745A (en) * 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
WO2005051301A2 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2012020742A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
CN109988105A (zh) * 2014-01-27 2019-07-09 天津滨江药物研发有限公司 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
AU2021311665A1 (en) * 2020-07-22 2023-03-16 Chugai Seiyaku Kabushiki Kaisha Composition containing arylamide derivative

Also Published As

Publication number Publication date
WO2022018875A1 (ja) 2022-01-27
KR20230098762A (ko) 2023-07-04
JP7168734B2 (ja) 2022-11-09
JP2022145416A (ja) 2022-10-04
KR20220012195A (ko) 2022-02-03
KR102550455B1 (ko) 2023-06-30
KR20230098762A9 (ko) 2024-03-25
JP2023011759A (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
BR112021014123A2 (xx)
JPWO2022018875A1 (xx)
BR102021018859A2 (xx)
BR102021015500A2 (xx)
BR102021007058A2 (xx)
BR102021020147A2 (xx)
BR102021018926A2 (xx)
BR102021018167A2 (xx)
BR102021017576A2 (xx)
BR102021016837A2 (xx)
BR102021016551A2 (xx)
BR102021016375A2 (xx)
BR102021016176A2 (xx)
BR102021016200A2 (xx)
BR102021015566A2 (xx)
BR102021015450A8 (xx)
BR102021015220A2 (xx)
BR102021015247A2 (xx)
BR102021014044A2 (xx)
BR102021014056A2 (xx)
BR102021013929A2 (xx)
BR102021012571A2 (xx)
BR102021012230A2 (xx)
BR102021012003A2 (xx)
BR102021012107A2 (xx)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630